title: Considerations for the upcoming FDA REMS proposal.
authors.forename: John F
authors.initials: JF
authors.lastname: Peppin
authors.forename: John J
authors.initials: JJ
authors.lastname: Coleman
authors.forename: Kenneth L
authors.initials: KL
authors.lastname: Kirsh
mesh_terms: D000701:Analgesics, Opioid; D003692:Delayed-Action Preparations; D011307:Drug Prescriptions / Q000592:standards; D005104:Expert Testimony; D006801:Humans; D009293:Opioid-Related Disorders / Q000453:epidemiology* / Q000517:prevention & control; D010146:Pain / Q000188:drug therapy; D010166:Palliative Care; D010353:Patient Education as Topic; D010600:Pharmacology / Q000193:education; D018570:Risk Assessment / Q000331:legislation & jurisprudence* / Q000592:standards*; D019966:Substance-Related Disorders / Q000453:epidemiology* / Q000517:prevention & control; D009626:Terminology as Topic; D014481:United States; D014486:United States Food and Drug Administration
chemical_list: D000701:Analgesics, Opioid; D003692:Delayed-Action Preparations